Methodological Considerations in N-of-1 Trials of Traditional Chinese Medicine

被引:2
|
作者
Huang, Haiyin [1 ]
An, Jiaqi [1 ]
Lu, Lizhi [1 ]
Wang, Mingli [1 ]
Chen, Huijia [1 ]
Chen, Xinlin [2 ]
Shen, Lihua [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China
[2] Guangzhou Univ Tradit Chinese Med, Basic Med Coll, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
D O I
10.1155/2021/6634134
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
More and more scholars choose N-of-1 trials for TCM clinical research. However, the quality of the experimental designs was uneven. Accumulating more than eight years of experience in exploring the N-of-1 trials of TCM, the authors and their team searched the related literature in main Chinese and English databases, referenced to relevant Chinese and international guidelines. The design, implementation, and data analysis of N-of-1 trials of TCM are still in in-depth exploration and practice. "Carryover effect" may affect the design and quality of the trials. Individualized treatment should be guided by the classic theories of TCM. It is expected to formulate reasonable observation periods and pairs and closely integrate individual and group statistical analysis.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Making N-of-1 Medicine a Reality
    Ho, Dean
    Zarrinpar, Ali
    SLAS TECHNOLOGY, 2017, 22 (03): : 231 - 232
  • [42] Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
    Silvestris, Nicola
    Ciliberto, Gennaro
    De Paoli, Paolo
    Apolone, Giovanni
    Lavitrano, Maria Luisa
    Pierotti, Marco A.
    Stanta, Giorgio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
  • [43] Traditional Chinese medicine needs clinical trials
    Penelope
    新世纪智能, 2019, (88) : 36 - 37
  • [44] Traditional Chinese Medicine Needs Clinical Trials
    Penelope
    新高考(英语进阶), 2017, (09) : 36 - 37
  • [45] Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
    Nicola Silvestris
    Gennaro Ciliberto
    Paolo De Paoli
    Giovanni Apolone
    Maria Luisa Lavitrano
    Marco A. Pierotti
    Giorgio Stanta
    Journal of Experimental & Clinical Cancer Research, 36
  • [46] Finding Benefit in n-of-1 Trials Reply
    Kravitz, Richard L.
    Schmid, Christopher H.
    Sim, Ida
    JAMA INTERNAL MEDICINE, 2019, 179 (03) : 455 - 455
  • [47] Understanding Variation in Sets of N-of-1 Trials
    Araujo, Artur
    Julious, Steven
    Senn, Stephen
    PLOS ONE, 2016, 11 (12):
  • [48] N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?
    Kravitz, Richard L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (06) : 781 - 782
  • [49] N-of-1 Trials in Cancer Drug Development
    Gouda, Mohamed A.
    Buschhorn, Lars
    Schneeweiss, Andreas
    Wahida, Adam
    Subbiah, Vivek
    CANCER DISCOVERY, 2023, 13 (06) : 1301 - 1309
  • [50] N-of-1 Trials in Neurology A Systematic Review
    Stunnenberg, Bas C.
    Berends, Joost
    Griggs, Robert C.
    Statland, Jeffrey
    Drost, Gea
    Nikles, Jane
    Groenewoud, Hans
    van Engelen, Baziel G. M.
    van der Gert, Wilt Jan
    Raaphorst, Joost
    NEUROLOGY, 2022, 98 (02) : E174 - E185